What We Do

Brava Diagnostics is developing acute care diagnostic products based on the MBio Diagnostics rapid testing platform. Our first applications will address unmet needs for assessment of chest pain and shortness of breath in the emergency department. Follow-on applications include diagnosis, staging and monitoring sepsis, the most expensive disease treated by hospitals.


Brava Diagnostics is assembling a world-class management team, scientists, board of directors and scientific advisory board. We are located in Boulder, Colorado. The combination of a thriving life science sector, awesome natural beauty and outstanding opportunities for outdoor activities makes Boulder a draw for top-notch talent.


Byron Hewett, Co-Founder and CEO

Byron has led healthcare and life science companies for more than 30 years, in multi-national firms, development-stage and start-up companies. His expertise is in general management, strategy, business development and sales and marketing.

From December 2013 to April 2017, he was CEO of SomaLogic, a life sciences tools company focused on biomarker discovery. From November 2008 to August 2013, Byron served as Chairman and CEO of BioBehavioral Diagnostics a start-up medical device company with the first FDA-cleared system for the assessment of ADHD. The Company was sold to Pearson in August, 2013. From 2006 to 2008, he served as chief executive officer and a director at Immunicon Corporation (NASDAQ: IMMC), the first FDA-cleared test for circulating tumor cells (CTC) for metastatic breast, colorectal and prostate cancer. From 2004-2006 Mr. Hewett served as Chief Operating Officer and President at Immunicon. The Company was sold to Johnson & Johnson in August, 2008. From 2002-2004, he served as Senior Vice President of sales and marketing and general manager, North America for Qiagen, Inc. where he led commercial North American operations. Byron has worked in healthcare and life science companies for more than 20 years in general management, strategy formulation, business development and sales and marketing with firms including Bayer Diagnostics (VP, U.S. Branch, and VP WW Marketing, Laboratory Testing Segment), Chiron Diagnostics (President, U.S. Commercial Operations), Biocircuits Corporation, Stericycle, Inc., and Abbott Laboratories.

Byron earned a Masters in Management degree from Northwestern University's J.L. Kellogg Graduate School of Management and a Bachelor’s of Science degree from the University of Virginia's McIntire School of Commerce.


David Okrongly, Ph.D., Co-Founder and Chief Operating Officer

Dave has been a business executive and R&D leader in the diagnostics industry, ranging from start-up to multi-national companies. He brings expertise in instrument and assay development, clinical trials, regulatory affairs and operations.

From July 2013 to December 2018, Dave served as President of OPKO diagnostics (OPKO Health, Inc. NYSE: OPK), a multi-national pharmaceutical and diagnostics company. He led the development and launch of the 4Kscore test for aggressive prostate cancer risk determination, a market leader in the pre-biopsy testing space and development of the Claros 1 point of care analyzer utilizing whole blood, finger stick samples to deliver quantitative test results in 10 minutes.  He served as chief operating officer of Exosome Diagnostics, Inc. from August 2011 – June 2013. Exosome Diagnostics is an early stage, venture-backed company developing molecular diagnostic tests based on proprietary technology for purifying RNA derived from exosomes. From 2009 to 2011, he was President and CEO for Quanterix Corporation (NASDQ: QTRX), a publicly company developing single molecule array immunoassay and molecular diagnostic technology for the life science and IVD markets. Dave held leadership positions with Bayer Diagnostics since 1997 and rose to global head of molecular diagnostics for Siemens Healthcare Diagnostics from 2007 to 2009.

Dave earned his PhD in Chemistry from Columbia University and a BSc with honors in Chemistry from University of Wisconsin-Madison.

Carrie Mulherin

Carrie Mulherin, Co-Founder and Chief Marketing Officer

Carrie is a marketing and sales executive with extensive start-up experience and 31 product launches. Carrie brings deep experience in strategic marketing, cross-functional team management and commercialization.

Carrie was CEO of Focus Marketing, an independent consulting agency, from November 2017. From August 2014 to October 2017, Carrie served as VP Diagnostics at SomaLogic. From 2009 to 2014, she was VP of Marketing and Sales for BioBDx/Pearson, a start-up medical device company. She served as Director of Marketing at OraSure Technologies in 2008-2009, managing the infectious disease rapid assay franchise. From 2002 to 2008, Carrie served as Vice President of Marketing and Sales at Immunicon Corporation, a development stage company in the liquid biopsy/cancer market. From 2000 to 2002, she worked at start-up diagnostics company, ThauMDx, which developed instruments and multiplex assays for point-of-care settings, including cardiac markers. From 1997 to 2000, she was Vice President of Sales and Marketing for Intracel Corporation. Carrie brings more than 20 years of sales, marketing and business development experience in the diagnostics, medical device, CRO and pharmaceutical industries.

Carrie earned a bachelor’s degree in molecular biology and biochemical sciences from Princeton University and an MBA in marketing from the University of Scranton.

Board of Directors

Robert J. Silverman, Chairman of the Board and Independent Director

Robert J. Silverman is the Board Chairman for Brava Diagnostics. Bob currently serves in a Board and Advisory capacity to a portfolio of companies including MBio Diagnostics, Kiyatec Inc., Lophius Biosciences GmbH, Pathovax LLC and Gilde Healthcare Venture Partners.

He served as the CEO of mtm laboratories AG, an in-vitro diagnostics company that developed and commercialized a portfolio of products for the early detection and diagnosis of cervical cancer. Bob was instrumental in raising capital and building mtm laboratories into a global, fully-integrated commercial business. He led the company to a $240 Million exit to Roche Diagnostics. Prior to leading mtm laboratories, he held senior executive positions at Viacell, Cytyc Corporation, Pasteur Merieux and Abbott Laboratories Pharmaceuticals.

He earned his Master’s Degree in Marketing and Finance from the Kellogg Graduate School of Management at Northwestern University. Bob received his B.S. in Pharmacy from the University of Michigan.

Byron Hewett, Chief Executive Officer, Brava Diagnostics

Christopher J. Myatt, Ph.D. Chief Executive Officer, MBio Diagnostics

Dr. Myatt is the founder and CEO of MBio Diagnostics, Inc. He is an entrepreneur with a proven track record for building technology companies, securing patents and licensing technology, raising funding, establishing commercial operations, and leading through growth. Prior to MBio Diagnostics, Chris successfully founded and led Precision Photonics Corporation, a successful laser and optical technology supplier that is now a division of IDEX. Trained as a physicist and measurement scientist, Chris invented and developed multiple technologies that formed the basis of his companies.

Chris earned a B.S. in Physics and a B.A. in Mathematics at Southern Methodist University. Chris also earned a Ph.D. in Atomic Physics at the University of Colorado. He studied Bose-Einstein Condensation (BEC) under Carl Wieman (Nobel Prize, 2001), helping to create the first BEC condensate in the Wieman lab. He also studied quantum information under David Wineland (Nobel Prize, 2012) as a National Research Council (NRC) Postdoctoral Fellow at the National Institute of Standards and Technology (NIST) in Boulder.

Learn More about the Team

Read short biographies on the executive team and Board.

Download our Fact Sheet

Download a 2-page summary about our strategy.

Schedule a Meeting

Brava is currently raising seed financing. Let's talk!